TY - JOUR
T1 - Aberrant lipid metabolism as a therapeutic target in liver cancer
AU - Pope, Evans D.
AU - Kimbrough, Erinmarie O.
AU - Vemireddy, Lalitha Padmanabha
AU - Surapaneni, Phani Keerthi
AU - Copland, John A.
AU - Mody, Kabir
N1 - Funding Information:
This research was funded in part by the following grants: Mayo Clinic Liver SPORE (NCI/NIH P50 CA210964; KM, JAC), NCI STTR R42 grant (CA195946; JAC) and Florida Department of Health (8BC01; JAC).
Funding Information:
K Mody has received research support from Agios, Senwha Biosciences, Taiho, ArQule, Astra Zeneca, Genentech, Incyte, Tracon Pharmaceuticals, Medimmune, Puma Biotechnology and consulting fees from Astra Zeneca, Bayer, Celgene, Eisai, Exelixis, Merrimack and Vicus JA Copland has filed a patent application for novel composition of matter for SCD1 inhibitors.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/6/3
Y1 - 2019/6/3
N2 - Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers. Progress has been made in treatment of HCC; however, improved outcomes are much needed. The increased metabolic needs of cancer cells underscore the importance of metabolic pathways in cancer cell survival. Lipid metabolism has a role in HCC development; aberrant overexpression of several key enzymes is seen in many solid human tumors. Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase. Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes.
AB - Introduction: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers. Progress has been made in treatment of HCC; however, improved outcomes are much needed. The increased metabolic needs of cancer cells underscore the importance of metabolic pathways in cancer cell survival. Lipid metabolism has a role in HCC development; aberrant overexpression of several key enzymes is seen in many solid human tumors. Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase. Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes.
KW - Fatty acid
KW - SCD1
KW - hepatocellular carcinoma
KW - lipid metabolism
KW - lipids
KW - liver cancer
KW - stearoyl co-A desaturase
UR - http://www.scopus.com/inward/record.url?scp=85065708943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065708943&partnerID=8YFLogxK
U2 - 10.1080/14728222.2019.1615883
DO - 10.1080/14728222.2019.1615883
M3 - Article
C2 - 31076001
AN - SCOPUS:85065708943
VL - 23
SP - 473
EP - 483
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
SN - 1472-8222
IS - 6
ER -